研究等業績 - その他 - 成田 伸太郎
-
Cisplatin unfitの進行性尿路上皮癌に対する二次化学療法としてのGemcitabine-Nedaplatin療法の有効性の検討
鶴田 大, 井上 高光, 齋藤 満, 前野 淳, 沼倉 一幸, 成田 伸太郎, 佐藤 滋, 羽渕 友則, 賀本 敏行
日本泌尿器科学会総会 ( (一社)日本泌尿器科学会総会事務局 ) 105回 PP75 - 03 2017年04月
-
分子標的薬時代の転移性腎癌における一次転移臓器別の予後解析
高山 孝一朗, 井上 高光, 喜早 祐介, 沼倉 一幸, 鶴田 大, 前野 淳, 齋藤 満, 成田 伸太郎, 佐藤 滋, 羽渕 友則
日本泌尿器科学会総会 ( (一社)日本泌尿器科学会総会事務局 ) 105回 OP49 - 4 2017年04月
-
当院および関連施設における去勢抵抗性前立腺癌に対するエンザルタミド、アビラテロンの治療成績
前野 淳, 沼倉 一幸, 鶴田 大, 齋藤 満, 成田 伸太郎, 井上 高光, 熊澤 光明, 飯沼 昌宏, 松尾 重樹, 佐藤 滋, 羽渕 友則
日本泌尿器科学会総会 ( (一社)日本泌尿器科学会総会事務局 ) 105回 PP53 - 04 2017年04月
-
根治的前立腺全摘患者の周術期血中サイトカイン濃度と生化学的再発の検討
奈良 健平, 成田 伸太郎, 沼倉 一幸, 鶴田 大, 前野 淳, 齋藤 満, 井上 高光, 佐藤 滋, 羽渕 友則
日本泌尿器科学会総会 ( (一社)日本泌尿器科学会総会事務局 ) 105回 PP91 - 06 2017年04月
-
腎移植レシピエント術後管理のコツと工夫
井上 高光, 齋藤 満, 成田 伸太郎, 佐藤 滋, 羽渕 友則
日本泌尿器科学会総会 ( (一社)日本泌尿器科学会総会事務局 ) 105回 UB07 - UB07 2017年04月
-
転移性腎癌におけるアキシチニブの治療効果を予測する血清バイオマーカーの探索
本間 直子, 土谷 順彦, 井上 高光, 鶴田 大, 前野 淳, 沼倉 一幸, 成田 伸太郎, 齋藤 満, 佐藤 滋, 羽渕 友則
日本泌尿器科学会総会 ( (一社)日本泌尿器科学会総会事務局 ) 105回 PP65 - 02 2017年04月
-
転移性腎癌患者における1st-line Sunitinib療法とAxitinib療法とのアウトカムの比較検討
喜早 祐介, 井上 高光, 高山 孝一朗, 沼倉 一幸, 鶴田 大, 斎藤 満, 前野 淳, 成田 伸太郎, 佐藤 滋, 羽渕 友則
日本泌尿器科学会総会 ( (一社)日本泌尿器科学会総会事務局 ) 105回 PP76 - 01 2017年04月
-
高齢腎移植レシピエントの選択基準について
齋藤 満, 佐藤 滋, 井上 高光, 沼倉 一幸, 成田 伸太郎, 鶴田 大, 羽渕 友則
日本泌尿器科学会総会 ( (一社)日本泌尿器科学会総会事務局 ) 105回 SKH04 - 1 2017年04月
-
Kobayashi M.
Acta Urologica Japonica ( Acta Urologica Japonica ) 63 ( 3 ) 111 - 114 2017年03月
-
Mizuki Kobayashi, Mitsuru Saito, Susumu Akihama, Teruaki Kumazawa, Ryoma Igarashi, Ryohei Yamamoto, Koichiro Takayama, Hiroshi Tsuruta, Takamitsu Inoue, Shintaro Narita, Norihiko Tsuchiya, Shigeru Satoh, Tomonori Habuchi
Hinyokika kiyo. Acta urologica Japonica ( 泌尿器科紀要刊行会 ) 63 ( 3 ) 111 - 114 2017年03月
A woman in her 30s was admitted with abdominal pain and nausea. CT scan revealed a spontaneous rupture of the right giant renal angiomyolipoma, and trans-arterial embolization was performed successfully. With further examination, she was found to be affected with tuberous sclerosis complex (TSC) and she finally wastreated with everolimusfor prevention of recurrent spontaneous-rupture of renal angiomyolipoma.
-
Kamba T.
International Journal of Clinical Oncology ( International Journal of Clinical Oncology ) 22 ( 1 ) 166 - 173 2017年02月
-
Ishikawa T.
International Journal of Molecular Sciences ( International Journal of Molecular Sciences ) 18 ( 2 ) 2017年02月
-
Ito R.
PLoS ONE ( PLoS ONE ) 12 ( 2 ) 2017年02月
-
【メタボリック症候群と腎泌尿器疾患-疾患予防への挑戦-】泌尿器がんとメタボリックシンドローム
成田 伸太郎, 井上 高光, 羽渕 友則
腎臓内科・泌尿器科 ( (有)科学評論社 ) 5 ( 2 ) 133 - 139 2017年02月
-
Numakura K.
Anti-Cancer Drugs ( Anti-Cancer Drugs ) 28 ( 1 ) 97 - 103 2017年01月
-
Laparoendoscopic single-site surgeries: A multicenter experience of 469 cases in Japan
Sato F.
International Journal of Urology ( International Journal of Urology ) 24 ( 1 ) 69 - 74 2017年01月
-
Narita T.
Medical Oncology ( Medical Oncology ) 34 ( 1 ) 2017年01月
-
Clinical effects of single nucleotide polymorphisms on drug-related genes in Japanese metastatic renal cell carcinoma patients treated with sunitinib.
Kazuyuki Numakura, Norihiko Tsuchiya, Hideaki Kagaya, Makoto Takahashi, Hiroshi Tsuruta, Takamitsu Inoue, Shintaro Narita, Mingguo Huang, Shigeru Satoh, Takenori Niioka, Masatomo Miura, Tomonori Habuchi
Anti-cancer drugs 28 ( 1 ) 97 - 103 2017年01月
Although sunitinib is a well-established chemotherapeutic for metastatic renal cell carcinoma (mRCC), there are no robust markers that predict efficacy and toxicity. We analyzed the effect of single nucleotide polymorphisms (SNPs) in genes involved in sunitinib pharmacokinetics on clinical outcomes in Japanese patients with mRCC. We analyzed the effect of SNPs in genes involved in sunitinib pharmacokinetics on the clinical outcome in mRCC patients in a Japanese population. We evaluated seven SNPs in four candidate genes, the transport proteins ATP-binding cassette (ABC) B1 (rs1045642, rs1128503, rs2032582, and rs7779562) and ABCG2 (rs2231142), and the metabolic proteins cytochrome P450 (CYP) 3A4 (rs35599367) and CYP3A5 (rs776746) in 70 patients. No significant association was observed between the genotypes of each SNP and time to dose reduction, progression-free survival, overall survival, and best objective response. Meanwhile, the incidence of grade 2 or greater hypertension and hand-foot syndrome, and multiple adverse events (>3), was significantly higher in patients carrying the ABCB1 rs2032582 GG genotype [odds ratio (OR): 5.37, 95% confidence interval (CI) 1.02-14.63, P=0.035; OR: 3.17, 95% CI 1.06-9.52, P=0.036, OR: 3.35; 95% CI 1.14-9.84; P=0.025, respectively]. In conclusion, our data showed that the ABCB1 rs2032582 GG genotype was associated with individual adverse events' susceptibility among Japanese patients treated with sunitinib in routine clinical settings.
-
The impact of extended lymph node dissection versus neoadjuvant therapy with limited lymph node dissection on biochemical recurrence in high-risk prostate cancer patients treated with radical prostatectomy: a multi-institutional analysis.
Takuma Narita, Takuya Koie, Teppei Ookubo, Koji Mitsuzuka, Shintaro Narita, Hayato Yamamoto, Takamitsu Inoue, Shingo Hatakeyama, Sadafumi Kawamura, Tatsuo Tochigi, Tomonori Habuchi, Yoichi Arai, Chikara Ohyama
Medical oncology (Northwood, London, England) 34 ( 1 ) 1 - 1 2017年01月
The optimal treatment for high-risk prostate cancer (Pca) remains to be established. The current guidelines recommend extended pelvic lymph node dissection (e-PLND) for selected intermediate- and high-risk patients treated with RP. However, the indications, optimal extent, and therapeutic benefits of e-PLND remain unclear. The aim of this study was to assess whether e-PLND confers an oncological benefit for high-risk Pca compared to neoadjuvant luteinizing hormone-releasing hormone and estramustine (LHRH + EMP). The Michinoku Urological Cancer Study Group database contained the data of 2403 consecutive Pca patients treated with RP at four institutes between March 2000 and December 2014. In the e-PLND group, we identified 238 high-risk Pca patients who underwent RP and e-PLND, with lymphatic tissue removal around the obturator and the external iliac regions, and hypogastric lymph node dissection. The neoadjuvant therapy with limited PLND (l-PLND) group included 280 high-risk Pca patients who underwent RP and removal of the obturator node chain between September 2005 and June 2014 at Hirosaki University. The outcome measure was BRFS. The 5-year biochemical recurrence-free survival rates for the neoadjuvant therapy with l-PLND group and e-PLND group were 84.9 and 54.7%, respectively (P < 0.0001). The operative time was significantly longer in the e-PLND group compared to that of the neoadjuvant therapy with l-PLND group. Grade 3/4 surgery-related complications were not identified in both groups. Although the present study was not randomized, neoadjuvant LHRH + EMP therapy followed by RP might reduce the risk of biochemical recurrence.
-
Huang M.
Oncotarget ( Oncotarget ) 8 ( 67 ) 111780 - 111794 2017年